Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Proteomic aptamer analysis reveals serum markers that characterize preclinical systemic sclerosis (SSc) patients at risk for progression toward definite SSc

Fig. 4

Distribution of categorized proteins in the validation cohort. Distribution of cases with high or low validated protein levels in preclinical systemic sclerosis patients who did evolve (progressors) or who did not (non-progressors) into definite systemic sclerosis. Dicothomization was performed as described in the main text; for endostatin risk is associated with high serum levels; for the basic fibroblast growth factor (FGF) and platelet-activating factor acetylhydrolase subunit beta (PAFAH1B2) risk is associated with low serum levels; clusterization made on the basis of serum concentrations

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us